It was the event for the ages, but I know that not everyone could attend.
I know we all struggle with being busy, and I genuinely feel bad if you missed this one. I’ve never had a response like this before…EVER.
To Watch the Replay of Kyle’s Option Rocket Webinar
>>> Click Here and Register <<<
You’ll receive your replay link in a few minutes.
—– Related —–
FREE DOWNLOAD
Kyle Dennis FREE EBOOK “The $2.9 Million Biotech Trader Playbook”
This book has helped thousands of other traders learn the basics of biotech, and how to easily spot winning trades.
Whether you are new trader or a 30-year veteran, this book will help you find stocks that are primed to make parabolic moves. These strategies are Kyle’s secret weapons that have help him net over $3 Million in profits…and they are all yours for free.
This is normally $97.00, but it’s yours FREE!
I took profits today on IDRA on some news that they are expanding their partnership with BMY. It was a nice piece of news before ASCO, and I’ll be looking to buy back shares tomorrow.
Biotech has slowed down here a bit – which is typical of this season. I’m watching intently for new names to add. Patience and timing is always key!
Catalyst Swing names (1 – 4 week holds) I am watching…
Idera Pharmaceuticals (IDRA)
Catalyst Dates: Phase 2 data due out June 4th and another Phase 2 data readout in June
Buy Zone: $1.75 to $1.95
Profit Zone: $2.20 or higher
Stop Zone: $1.70 or below
Aquinox Pharmaceuticals (AQXP)
Catalyst Dates: Phase 3 data due out in the third quarter
Buy Zone: $12.00 to $13.00
Profit Zone: $16.00 or higher
Stop Zone: $11.50 or below
Bellerophon Therapeutics (BLPH)
Catalyst Dates: Interim Phase 3 data release in the middle of 2018 (likely late June or July)
Buy Zone: $2.20 to $2.40
Profit Zone: $2.75 or higher
Stop Zone: $2.10 or below
Durect Corporation (DRRX)
Catalyst Dates: Advisory Committee meeting on June 26th, FDA Approval dates on July 28th and August 7th.
Buy Zone: $1.75 to $2.00
Profit Zone: $2.40 or higher
Stop Zone: $1.65 or below
Array BioPharma (ARRY)
Catalyst Dates: Phase 3 data due out June 20-23 FDA approval date of June 30 as well.
Buy Zone: $14.50 to $15.50
Profit Zone: $18.00 or higher
Stop Zone: $14.00 or below
Global Blood Therapeutics (GBT)
Catalyst Dates: Phase 3 data likely due out in June. Officially in the “first half”
Buy Zone: $46.00 to $48.00
Profit Zone: $54.00 or higher
Stop Zone: $44.00 or below
Pluristem Therapeutics (PSTI)
Catalyst Dates: Phase 2 data due out to be published in June.
Buy Zone: $1.30 to $1.45
Profit Zone: $1.80 or higher
Stop Zone: $1.20 or below
Marinus Pharmaceuticals (MRNS)
Catalyst Dates: Phase 2 data due out in the third quarter. Two other Phase 2 datas due out in the fourth quarter.
Buy Zone: $4.25 to $4.75
Profit Zone: $6.00 or higher
Stop Zone: $4.00 or below
Cytokinetics Incorporated (CYTK)
Catalyst Dates: Phase 2 data due out June 16
Buy Zone: $8.50 to $9.00
Profit Zone: $10.00 or higher
Stop Zone: $7.40 or below
Zogenix (ZGNX)
Catalyst Dates: Phase 3 data due late June or early July
Buy Zone: $39.50 to $40.50
Profit Zone: $45.00 or higher
Stop Zone: $37.50 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Phase 2 data in July
Buy Zone: $26.50 to $28.50
Profit Zone: $33.00 or higher
Stop Zone: $25.00 or below
Pain Therapeutics (PTIE)
Catalyst Dates: Advisory Committee Meeting June 26th and FDA approval date of August 7th
Buy Zone: $7.50 to $8.25
Profit Zone: $9.50 or higher
Stop Zone: $7.00 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.